Medtronic Stock Gains as CMS Proposes Coverage for Renal Denervation

Medtronic stock gains as CMS proposes coverage for renal denervation

Recor Medical Supports Proposed CMS National Coverage Determination of Renal Denervation for ...

Palo Alto, CA, July 10, 2025 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced their support for the Centers for Medicare and Medicaid Services’ (CMS) proposed National…

With Medtronic's next-gen RDN devices and procedures advancing, Project Galileo is next

Medtronic Renal Denervation GM Jason Fontana offers an update on new Symplicity Spyral devices, procedures and a feature they’re investigating. Medtronic’s renal denervation (RDN) business is in the early stages of a new project to add a key feature to its minimally invasive hypertension technology as it makes progress on a new catheter design and… The post With Medtronic’s next-gen RDN devices and procedures advancing, Project Galileo is next a…

CMS recommends coverage for renal denervation for hypertension - Interventional News

The US Centres for Medicare & Medicaid Services (CMS) has issued its proposed National Coverage Determination (NCD) on renal denervation, recommending coverage for the therapy for the treatment of uncontrolled hypertension. A 30-day public comment period is pen for healthcare professionals, professional societies, and industry to provide input before CMS issues its final determination in October. Renal denervation is a treatment for individuals …

CMS recommends coverage for renal denervation for hypertension - Cardiovascular News

The US Centres for Medicare & Medicaid Services (CMS) has issued its proposed National Coverage Determination (NCD) on renal denervation, recommending coverage for the therapy for the treatment of uncontrolled hypertension. A 30-day public comment period is pen for healthcare professionals, professional societies, and industry to provide input before CMS issues its final determination in October. Renal denervation is a treatment for individuals …

CMS Seeks Comments on Proposed Decision Memo for RDN to Treat Hypertension - Endovascular Today

July 10, 2025—The Centers for Medicare & Medicaid Services (CMS) issued a proposed decision memo for its National Coverage Analysis (NCA) of renal denervation (RDN)—including radiofrequency (rfRDN) and ultrasound (uRDN) treatments—for uncontrolled hypertension under Coverage with Evidence Development (CED). CMS stated it is seeking comments on the proposed decision with a comment period from July 10 to August 9, 2025. The proposed decision memo …